Bone Marrow Transplantation (BMT) is a useful strategy for the treatment of leukemia, severe combined immune deficiency, enzyme deficiencies, autoimmune disease, and osteoporosis. Furthermore, BMT plays an important role in the induction of immune tolerance in organ transplantation. Bone marrow is a spongy tissue, and is made up of Hematopietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs), and various blood cells. HSCs differentiate into common myeloid- and lymphoid-precursor cells and then terminally differentiate into erythrocytes, monocytes, platelets, neutrophils, dendritic cells and other cells. MSCs can differentiate into not only mesoderm derived-cells such as adipocytes, osteoblasts, and osteoclasts, but also endodermand ectoderm-derived cells. Intra-Bone Marrow-BMT (IBM-BMT) has been proven to be the best strategy for allogeneic BMT as it results in the rapid recovery of hemopoietic function and the restoration of T cell functions since it can replace not only HSCs but also MSCs.
Susumu Ikehara, Advances in Leukemia Treatment with Bone Marrow Transplantation
OMICS Group International through its scholarly open access initiative is committed to make genuine and reliable contributions to the scientific community. It provides the best way to publish the original research work through best open access journals allowing researchers, potential learners and the academic fellow from respective domain to access the same works for free, which also results in quick dissemination of findings and a wide impact.
OMICS Group International is a scientific organization that promotes open access for relevant scientific information and research findings. About 700+ peer-reviewed journals are handled by more than 25000 editorial board members who belong to both academic and industrial circles in all aspects of Science, Engineering, Management and Technology journals.
Last date updated on July, 2014